Recent news highlights include FDA breakthrough therapy designation for lacutamab, workforce reductions, shrinking net loss in H1 2025, revenue declines in Q1 2025, and active trading interest in late 2025.

• Innate Pharma received FDA Breakthrough Therapy Designation for lacutamab for relapsed/refractory Sezary syndrome [N8].
• The company reported a shrinking net loss in the first half of 2025 and announced plans for a 30% workforce reduction [N5].
• Innate Pharma’s Q1 2025 revenue declined, accompanied by a stock price decrease [N6].
• The stock formed a 'hammer chart pattern' in November 2025, indicating notable trading activity [N3].
• BTIG reiterated a buy recommendation for Innate Pharma in October 2025 [N4].
• Innate Pharma was among the most active pre-market traded stocks on November 10, 2025 [N2].
• Search interest in Innate Pharma spiked in early 2026, reflecting increased market attention [N1].

Innate Pharma’s innovative approach to cancer immunotherapy leveraging the innate immune system and its proprietary ANKET® platform could address unmet medical needs across multiple tumor types. Collaborations with major pharmaceutical companies provide financial support and validation of its technology. The FDA’s breakthrough therapy designation for lacutamab highlights potential clinical promise. Cost management initiatives such as workforce reductions may improve operational efficiency. Continued progress in clinical trials and successful milestone achievements could enhance the company’s value proposition and partnership opportunities.

Innate Pharma faces significant risks including continued net losses, the need for additional financing beyond current liquidity, and uncertainties inherent in clinical development and regulatory approval processes. Declining revenue from collaboration agreements reflects the completion of certain programs, which may pressure near-term financial performance. The company’s dependence on milestone payments and partner collaborations introduces variability and uncertainty in revenue streams. Foreign exchange risks and potential impairments of intangible assets add to financial risks. Failure to achieve clinical or commercial milestones could adversely impact the company’s prospects and financial condition.

Innate Pharma’s moat is based on its proprietary immunotherapy platforms, including the ANKET® technology for NK cell engagers, and its portfolio of clinical-stage product candidates targeting cancer. Strategic collaborations with established pharmaceutical companies such as AstraZeneca and Sanofi provide access to resources, expertise, and milestone payments that support development and commercialization efforts. The company’s specialized focus on harnessing the innate immune system and its intellectual property portfolio contribute to competitive differentiation. However, as a clinical-stage biotech firm, the moat is contingent on successful clinical development, regulatory approvals, and commercialization of its product candidates, which remain subject to significant risks and uncertainties.

• Financing Risk: The company’s liquidity is sufficient to fund operations only through Q3 2026, requiring additional financing to continue operations beyond that period. Failure to secure financing on acceptable terms could impact the company’s ability to continue as a going concern.
• Clinical and Regulatory Risk: Innate Pharma’s product candidates are in clinical development and subject to risks of failure in clinical trials, regulatory delays, or non-approval, which could materially affect the company’s business and financial condition.
• Revenue Concentration and Variability: Revenue depends heavily on milestone payments and collaboration agreements with a few major partners such as AstraZeneca and Sanofi. The timing and achievement of milestones are uncertain and outside the company’s full control.
• Foreign Exchange Risk: The company is exposed to foreign currency exchange risk due to U.S. dollar-denominated operations and payments, which may impact financial results given currency fluctuations.
• Impairment Risk: The company has recognized impairments on intangible assets related to discontinued programs. Future impairments could occur if clinical or commercial prospects deteriorate.

• Innate Pharma SA is a clinical-stage biotechnology company focused on developing immunotherapies for cancer patients by harnessing the innate immune system.
• The company’s therapeutic approaches include monoclonal antibodies, multispecific NK Cell Engagers via its proprietary ANKET® platform, and Antibody Drug Conjugates (ADC).
• Key proprietary programs include lacutamab for cutaneous and peripheral T cell lymphomas, monalizumab developed with AstraZeneca for non-small cell lung cancer, several ANKET® drug candidates for multiple tumor types, and IPH4502 ADC for solid tumors.
• Innate Pharma has collaboration and licensing agreements with major pharmaceutical companies such as AstraZeneca, Sanofi, and Takeda, which provide upfront payments, milestone payments, and research funding.
• Revenue primarily derives from collaboration and licensing agreements and government financing for research expenditures, including research tax credits.
• For the fiscal year ended December 31, 2025, the company reported revenue of €9.0 million and a net loss of €49.2 million, with basic and diluted EPS of -0.55 EUR per share.
• As of December 31, 2025, Innate Pharma had cash and cash equivalents of €28.1 million, short-term investments of €6.2 million, current assets of €46.7 million, and current liabilities of €36.6 million, resulting in a current ratio of 1.27 and a cash ratio of 0.94.
• The company’s liquidity position as of December 31, 2025, is sufficient to fund operations until the end of the third quarter of 2026, but additional financing will be required thereafter to continue operations.
• Innate Pharma has incurred net losses in most years since inception, primarily due to research and development expenses and selling, general and administrative costs.
• The company has recognized impairments on intangible assets, notably a €41.0 million impairment related to discontinuation of avdoralimab development in bullous pemphigoid indication.
• Innate Pharma’s revenue from collaboration agreements decreased significantly from €51.9 million in 2023 to €12.6 million in 2024 and further to €2.8 million in 2025, reflecting the progression and completion of certain agreements.
• The company’s collaboration with AstraZeneca includes monalizumab and IPH5201 programs, with milestone payments and cost-sharing arrangements for clinical trials.
• Innate Pharma regained full rights to the IPH67 NK Cell Engager program after Sanofi terminated the license agreement in 2024, with Sanofi retaining low single-digit royalties on future revenues.
• The company’s revenue and income recognition policies for collaboration agreements involve deferring upfront payments and recognizing revenue based on percentage of completion and milestone achievement.
• Innate Pharma’s ADSs are listed on the Nasdaq Global Select Market and are considered readily tradable securities in the United States.
• The company is incorporated under French law and is subject to French foreign exchange regulations and taxation, with specific U.S. federal income tax considerations for U.S. holders of its ADSs.
• Innate Pharma received FDA Breakthrough Therapy Designation for lacutamab for relapsed/refractory Sezary syndrome.
• Recent news highlights include workforce reduction plans, shrinking net loss in H1 2025, revenue declines in Q1 2025, and active trading interest in late 2025.
• The company’s financial income includes interest and gains on financial assets, with net financial income of €4.8 million in 2025.
• Innate Pharma’s business risks include the need for additional financing, clinical trial outcomes, regulatory approvals, and foreign exchange risks due to U.S. dollar exposure.
• The company’s collaborations involve milestone payments contingent on scientific, regulatory, and commercial achievements, which are uncertain and outside the company’s full control.